Skip to main content

Table 2 Association between TopIIα and Ki67 expression and clinical variables

From: Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer

Clinical variables

TopIIα expression (%)

P

Ki67 expression (%)

P

 

High

Low

 

High

Low

 

Sex

      

   Male

25 (22.5)

86 (77.5)

0.998

39 (35.1)

72 (64.9)

0.584

   Female

9 (22.5)

31 (77.5)

 

16 (40.0)

24 (60.0)

 

Smoking status

      

   No

16 (24.6)

49 (75.4)

0.591

25 (38.5)

40 (61.5)

0.651

   Yes

18 (20.9)

68 (79.1)

 

30 (34.9)

56 (65.1)

 

Histology

      

   Adenocarcinoma

14 (23.7)

45 (76.3)

0.775

22 (37.3)

37 (62.7)

0.860

   Non- adenocarcinoma

20 (21.7)

72 (78.3)

 

33 (35.9)

59 (64.1)

 

Stage

      

   I

10 (18.5)

44 (81.5)

0.177

13 (24.1)

41 (75.9)

0.034*

   II

15 (31.9)

32 (68.1)

 

23 (48.9)

24 (51.1)

 

   III

9 (18.0)

41 (82.0)

 

19 (38.0)

31 (62.0)

 

T stage

      

T1

13 (34.2)

25 (65.8)

0.148

18 (47.4)

20 (52.6)

0.168

T2

18 (18.2)

81 (81.8)

 

34 (34.3)

65 (65.7)

 

T3-4

3 (21.4)

11 (78.6)

 

3 (21.4)

11 (78.6)

 

N stage

      

N0

12 (19.4)

50 (80.6)

0.137

16 (25.8)

46 (74.2)

0.065

N1

16 (32.0)

34 (68.0)

 

23 (46.0)

27 (54.0)

 

N2

6 (15.4)

33 (84.6)

 

16 (41.0)

23 (59.0)

 
  1. * P < 0.05 was considered statistically significant